drugset / Trial / NCT02943733
Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic NETs
Phase 1
Terminated
18 enrolled
University of Wisconsin, Madison
Taiho Pharmaceutical Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
The goal of this study is to establish maximum tolerated doses/recommended phase 2 dose (RP2D) of temozolomide (TMZ) and TAS-102 when these agents are used in combination and to evaluate the safety profile of this drug combination.
Timeline
- Start
- 2017-08-22
- Primary completion
- 2020-11-07
- Completion
- 2022-01-31
Outcome
Outcome not reported
Stopped (Enrollment): “closed per sponsor request, for slow enrollment”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TAS-102 | Small molecule | — | Oral |
| Subject | Temozolomide | Small molecule | — | Oral |
| Background | Pegfilgrastim | Protein / enzyme biologic | — | — |
| Background | filgrastim | Protein / enzyme biologic | — | — |